Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company OSE Immunotherapeutics S.A.
DescriptionSecond-generation checkpoint inhibitor that blocks signal regulatory protein alpha (SIRPA)
Molecular Target Signal regulatory protein alpha (SIRPA)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationLiver cancer
Indication DetailsTreat primary liver cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today